Executive Interviews

41. The Rise Of Computational Biology In Biopharma 12/1/2022

    I thought I’d peel a layer off the onion to reveal a trend that’s gaining momentum and having a positive impact during a somewhat negative biopharma news cycle: computational biology.

42. How Are DCTs Impacting Your Clinical Sites? 12/1/2022

    Where do your sites stand on DCTs? For this article, we spoke with three site experts who discussed the pain points of DCTs, including costs, budgeting, training, support, staffing, resources, and more.

43. Building New Solutions For 2023 In Manufacturing And Supply Chain 12/1/2022

    In this Q&A, 10 executives provide their thoughts on what the future holds for biopharmaceutical manufacturing and supply chain operations, and which issues will have the most impact.

44. How To Reduce COGS & Expedite Commercial-Scale CGT Manufacturing 12/1/2022

    Industry luminaries from Kite Pharma, Novartis Gene Therapies, and SwanBio share their knowledge on why the road to cost-efficient and timely commercial manufacturing for cell and gene therapies (CGTs) is paved with AI, automation, clinical trial design, AAV vector efficiencies, skilled team members, and more.

45. Managing Through Mixed Trial Results And An Economic Downturn 11/1/2022

    From mixed topline results from a Phase 3 trial of lead candidate to the potential need to fund and conduct another trial prior to seeking regulatory approval, Cary Claiborne has been faced with multiple challenges since becoming CEO of Adial Pharma in August.

46. Imagine Pharma's Multilayered Path To Market 10/3/2022

    From the looks of its modest open floor plan lab in Pittsburgh’s uptown, it might not be obvious to the casual observer that Imagine Pharma and its nine-person full-time workforce are developing multiple pharmaceutical products across three distinct platforms.

47. The Discovering CEO 10/3/2022

    In the current world of biopharma companies, the discovery function covers much more than hammering out new drug entities.

48. Nonprofit Pursues Oncology Drugs 9/1/2022

    RebootRX believes that many off-patent pharmaceuticals have cancer-fighting potential, but their generic status makes them unattractive commercial candidates for profit-making pharmas.

49. Conducting A Drug Development Orchestra To Treat Mental Illness 9/1/2022

    Karuna Therapeutics’ late-stage drug for schizophrenia, if approved, could fund the company’s pipeline of next generation psychiatric drugs discovered through a modular constellation of CRO partners.

50. Bayer Brings External Innovation Inside, With Guardrails 9/1/2022

    Can Bayer’s “arm’s-length model” for acquired companies help turn the century-and-a-half year-old Big Pharma into a leader in gene and cell therapy, and a top 10 player in oncology?